Price T Rowe Associates Inc. MD Increases Stock Position in ICU Medical, Inc. (NASDAQ:ICUI)

Price T Rowe Associates Inc. MD grew its position in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 17.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,772 shares of the medical instruments supplier's stock after acquiring an additional 2,578 shares during the quarter. Price T Rowe Associates Inc. MD owned 0.07% of ICU Medical worth $2,758,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ICUI. Vanguard Group Inc. lifted its position in shares of ICU Medical by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 2,682,065 shares of the medical instruments supplier's stock worth $416,176,000 after acquiring an additional 17,805 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of ICU Medical by 7.4% in the 4th quarter. JPMorgan Chase & Co. now owns 708,382 shares of the medical instruments supplier's stock valued at $109,920,000 after purchasing an additional 49,108 shares in the last quarter. Dimensional Fund Advisors LP raised its position in ICU Medical by 18.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 539,981 shares of the medical instruments supplier's stock worth $83,788,000 after purchasing an additional 82,982 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in ICU Medical by 1.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 304,155 shares of the medical instruments supplier's stock worth $47,196,000 after purchasing an additional 3,048 shares during the last quarter. Finally, Norges Bank bought a new position in ICU Medical during the 4th quarter worth approximately $40,151,000. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

ICU Medical Stock Down 3.2 %

ICUI traded down $4.57 during trading on Friday, reaching $138.30. The stock had a trading volume of 622,758 shares, compared to its average volume of 274,740. ICU Medical, Inc. has a one year low of $100.91 and a one year high of $196.26. The company has a market capitalization of $3.40 billion, a price-to-earnings ratio of -30.26 and a beta of 0.87. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The stock's 50 day moving average is $140.67 and its two-hundred day moving average is $155.13.

ICU Medical (NASDAQ:ICUI - Get Free Report) last released its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.49. The firm had revenue of $599.49 million during the quarter, compared to analyst estimates of $574.15 million. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. The business's revenue was up 6.7% on a year-over-year basis. During the same period last year, the business earned $0.96 earnings per share. As a group, analysts expect that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have weighed in on ICUI. StockNews.com cut shares of ICU Medical from a "buy" rating to a "hold" rating in a research report on Saturday. KeyCorp cut their target price on ICU Medical from $209.00 to $191.00 and set an "overweight" rating on the stock in a research note on Monday, April 21st. Raymond James cut their price objective on ICU Medical from $197.00 to $187.00 and set a "strong-buy" rating on the stock in a research report on Friday. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of ICU Medical in a research note on Tuesday, April 8th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $192.67.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.